PGDx elio tissue complete

About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) is a commercial-stage precision oncology diagnostics company, now a subsidiary of Labcorp following its 2022 acquisition. Its core offering is the PGDx elio™ portfolio, which includes FDA-cleared and CE-IVD marked kitted solutions for tissue and liquid biopsy-based comprehensive genomic profiling, backed by proprietary bioinformatics. The company targets the global market for distributed cancer diagnostics, serving both clinical laboratories and biopharma partners through its products and services. Its strategy focuses on removing barriers to testing by enabling local labs to perform rapid, in-house genomic analysis to guide personalized treatment decisions.

Therapeutic Areas